Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Schrödinger Inc.

    NASDAQ: SDGR · Real-Time Price · USD
    20.05
    0.68 (3.48%)
    At close: Aug 18, 2025, 3:59 PM
    20.09
    0.22%
    After-hours: Aug 18, 2025, 07:59 PM EDT
    3.48%
    Bid 19.92
    Market Cap 1.48B
    Revenue (ttm) 237.92M
    Net Income (ttm) -181.33M
    EPS (ttm) -2.48
    PE Ratio (ttm) -8.08
    Forward PE -9.83
    Analyst Buy
    Ask 20.13
    Volume 1,142,799
    Avg. Volume (20D) 1,241,169
    Open 19.37
    Previous Close 19.38
    Day's Range 19.03 - 20.18
    52-Week Range 16.60 - 28.47
    Beta 1.68

    About SDGR

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SDGR
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SDGR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Schrödinger Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    5 days ago
    -1.97%
    Schrodinger shares are trading lower after the com... Unlock content with Pro Subscription
    2 months ago
    -14.42%
    Schrodinger shares are trading lower. The company announced initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies.
    news image

    4 days ago · businesswire.com

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's comm...

    news image

    5 days ago · businesswire.com

    Schrödinger Announces Discontinuation of SGR-2921 Program

    NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Pha...

    news image

    1 week ago · seekingalpha.com

    Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

    Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jaren Irene Madden - Chief Corporate Affairs Officer & Head of Investor Relations Karen...

    news image

    1 week ago · zacks.com

    Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

    Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.74 per share a year ago.

    news image

    1 week ago · fool.com

    Schrödinger (SDGR) Q2 2025 Earnings Transcript

    Image source: The Motley Fool.

    news image

    1 week ago · businesswire.com

    Schrödinger Reports Second Quarter 2025 Financial Results

    NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the quarter ended June 30, 2025.

    news image

    3 weeks ago · businesswire.com

    Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

    NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a con...

    news image

    3 weeks ago · zacks.com

    Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · businesswire.com

    Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

    NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus...

    news image

    1 month ago · businesswire.com

    Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

    NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administ...

    Add to Watchlist